---
type: entity
entity_type: company
name: Orbicular Pharmaceutical Technologies
domain: health
status: active
founded: null
headquarters: null
website: null
tags: [generic-pharmaceuticals, semaglutide, GLP-1, formulation]
---

# Orbicular Pharmaceutical Technologies

Pharmaceutical formulation development company.

## Overview

Orbicular Pharmaceutical Technologies partnered with Apotex on the development of generic semaglutide injection that received first US FDA tentative approval.

## Timeline

- **2026-04-10** — Partnership with Apotex received first US FDA tentative approval for generic semaglutide injection (ANDA). Orbicular provided formulation development expertise for the generic version.